Red marrow doses were higher for 177Lu-PSMA-617 than estimated for 64Cu-DOTHA2-PSMA, but this could be in part due to bone metastasis in patients for 177Lu-PSMA-617 (46–48). Here, FOLH1 is linked to bone metastasis.